Investigational drug · Phase 2
TK216
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sarcoma, Ewing.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "TK216"
First trial start
2024
Mar 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TK216", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcoma, Ewing
Largest trials
Live from ClinicalTrials.gov: studies naming "TK216" as an intervention, largest first.
Oncternal Therapeutics, IncIndustry
NCT02657005 · 85 participants · Start Aug 2016 · Primary completion May 2022
Drug: TK216 · For: Sarcoma, Ewing
Sites: Los Angeles, California; Aurora, Colorado; Washington D.C., District of Columbia · 9 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05046314 · 15 participants · Start Mar 12, 2024 · Primary completion Feb 5, 2025
Drug: TK216+Vincristin · For: Sarcoma, Ewing
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 8 sites in all
- TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid LeukemiaWithdrawn
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03752138 · 0 participants · Start Mar 31, 2019 · Primary completion Dec 31, 2020
Drug: Group 1: TK216; Group 2: TK216 and 5 more · For: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Newest research
PubMed records naming it or its code names, newest first.
- Neutrophil Extracellular Traps-Mediated Intraplaque Angiogenesis and Microvascular Permeability Promote Rapid Plaque Progression following Myocardial Infarction.
Lei Z, Yin Y, Zeng L, et al. · Research (Wash D C) 2026
- Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.
Asmar C, Asmar R, Awad G, et al. · Clin Transl Oncol 2026
- A predictive 14-gene signature and FLI1 inhibition overcome tumor-infiltrating lymphocyte dysfunction in triple-negative breast cancer.
Jia M, Jiang L, Han S, et al. · Biochem Biophys Res Commun 2026
- Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.
Spriano F, Cascione L, Tarantelli C, et al. · Cancer Med 2026
- ETS1 potentiates pancreatic Pyroptosis in mice with acute pancreatitis by regulating the NKIRAS1/NF-κB Axis.
Xia W, Su H, Huang Y, et al. · Int Immunopharmacol 2026
- Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
Meyers PA, Federman N, Daw N, et al. · J Clin Oncol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.